Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Large Is the Hepatitis Drugs Market Expected to Be in 2029?
The market for hepatitis drugs has seen consistent growth over the past few years. The market is projected to expand from a size of $20.04 billion in 2024 to $20.78 billion in 2025, registering a compound annual growth rate (CAGR) of 3.7%. The historical growth has been spurred on by factors such as the development of antiviral drugs specifically designed to combat hepatitis viruses, progress in hepatitis diagnostic technologies, growing understanding of global hepatitis prevalence, the expansion of hepatitis immunisation programs, and the creation of hepatitis therapies based on interferon.
In the upcoming years, it’s anticipated that the hepatitis drugs market will experience consistent growth, ballooning to “$24.21 billion in 2029 at a compound annual growth rate (CAGR) of 3.9%”. This expected increase during the projected period is owed to several factors, such as the launch of innovative direct-acting antiviral medications, surging cases of hepatitis infections, escalated efforts by governments for preventing and treating hepatitis, advancements in personalized medicine for hepatitis, and enhanced accessibility to hepatitis drugs in developing nations. The period is also set to witness a shift from interferon-based to interferon-free treatments, the evolution of pan-genotypic antiviral drugs for hepatitis C, the adoption of non-invasive diagnostic techniques for assessing liver fibrosis, the exploration of combination treatments for hepatitis B, and an increased emphasis on eradicating viral hepatitis as a threat to public health.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6889&type=smp
What Are The Contributors To Demand In The Hepatitis Drugs Market?
The surge in the incidence rate of various types of hepatitis is a significant factor propelling the hepatitis drug market’s growth. The requirement for distinct types of medication for different forms of hepatitis escalates the demand for hepatitis drugs. For example, the World Health Organization (WHO), an international public health entity based in Switzerland, reported in June 2022 that 296 million people suffered from chronic hepatitis B, with around 1.5 million new infections annually. This upward trend in hepatitis infections will inevitably heighten the requirement and usage of hepatitis drugs. Hence, the rise in different forms of hepatitis is anticipated to fuel the expansion of the hepatitis drug market in the predicted period.
What Segmentation Categories Are Included In The Hepatitis Drugs Market Analysis?
The hepatitis drugs market covered in this report is segmented –
1) By Drug Class: Interferon Alphas, HIV NRTIs, Nucleotide Polymerase Or NS5A Inhibitor Combinations, Hepatitis C Protease Or NS5A Inhibitor Combinations, NS5A Inhibitors, Nucleotide Polymerase Inhibitors, Nucleoside Analogue Antivirals, Thrombopoiesis Stimulating Agents
2) By Route Of Administration: Oral, Injection
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By Application: Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, Hepatitis E
Subsegments:
1) By Interferon Alphas: Pegylated Interferon Alpha, Non-Pegylated Interferon Alpha
2) By HIV NRTIs: Zidovudine, Lamivudine, Abacavir, Tenofovir
3) By Nucleotide Polymerase Or NS5A Inhibitor Combinations: Sofosbuvir Or velpatasvir, Sofosbuvir Or ledipasvir
4) By Hepatitis C Protease Or NS5A Inhibitor Combinations: Glecaprevir Or pibrentasvir, Paritaprevir Or ombitasvir Or dasabuvir
5) By NS5A Inhibitors: Daclatasvir, Ledipasvir, Velpatasvir
6) By Nucleotide Polymerase Inhibitors: Sofosbuvir, Dasabuvir
7) By Nucleoside Analogue Antivirals: Adefovir, Entecavir, Lamivudine
8) By Thrombopoiesis Stimulating Agents: Eltrombopag, Romiplostim
What Notable Trends Are Shaping The Direction Of The Hepatitis Drugs Market?
Significant enterprises operating within the hepatitis drugs market are concentrating on creating innovative drug formulations. The aim is to improve treatment effectiveness, patient adherence, reduce possible complications, and counter the various types of the hepatitis virus. The FDA Fast Track program is a specialized protocol engineered to speed up the evaluation and development of medications addressing severe medical conditions and those fulfilling unfulfilled health requirements. Medications receiving this recognition are geared towards helping patients access new treatments at a quicker pace, specifically for life-threatening or critical conditions. For example, in February 2024, Fast Track recognition was granted by The U.S. Food and Drug Administration (FDA) to GSK plc, a pharmaceutical company based in the UK, for their drug bepirovirsen, intended to treat chronic hepatitis B (CHB). This acknowledgment is of significance as it’s aimed to fast-track the evaluation and development of treatments that attend to unmet health necessities in serious situations.
Who Are The Top-Ranked Companies In The Hepatitis Drugs Market Today?
Major companies operating in the hepatitis drugs market include Gilead Sciences Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc., Abbott Laboratories, AbbVie Inc., Arbutus Biopharma Corporation, Aspen Pharmacare Holdings Limited, Aurobindo Pharma Limited, Beximco Pharmaceuticals Ltd., Biocon Limited, Bristol-Myers Squibb Company, Cadila Healthcare Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Enanta Pharmaceuticals Inc., Hetero Drugs Limited, Laurus Labs Limited, Lupin Pharmaceuticals Inc., Micro Labs Limited, Mylan N. V., Natco Pharma Limited, Novartis International AG, Roche Holding AG, Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., Zydus Cadila Healthcare Limited, Vir Biotechnology Inc., Genentech Inc., Eisai Pharmaceuticals India Pvt. Ltd.
Get The Full Report Here:
https://www.thebusinessresearchcompany.com/report/hepatitis-drugs-global-market-report
How Is Hepatitis Drugs Market Adoption Varying Across Different Regions And Sectors?
North America was the largest region in the hepatitis drugs market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hepatitis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=6889&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
